Feed AVDL
AV

Avadel Pharmaceuticals plc

AVDL · NASDAQ

$21.64 +0.00% (+$0.00)
Market Cap $2.12B
P/E Ratio -
Div. Yield -
ROE 0.33%
Piotroski F-Score Moderate
4/9
Valuation
0 /100
Expensive
P/FCF 59.99x
P/B 21.62x
EV/EBITDA 205.49x
Growth
-
N/A
Book val. growth N/A
FCF growth N/A
EPS growth N/A
Profitability
49 /100
Moderate
FCF margin 14.25%
Op. margin 1.82%
Gross margin 94.47%
Quality
16 /100
Poor
Asset turnover 1.25x
ROA 0.14%
ROIC 0.28%
Debt
80 /100
Low
Net debt/EBITDA -4.19x
Int. coverage 0.66x
Debt/Equity 0.38x
Stability
19 /100
Unstable
EPS volatility 662.55%
Profitable years 0
Beta 1.31x

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about AVDL
Online

About the company

Avadel Pharmaceuticals plc (AVDL) is an Irish pharmaceutical company focused on the development and commercialization of medicines for the treatment of neurological and cardiovascular diseases. With a product portfolio including drugs such as FT218 and Noctiva, Avadel Pharmaceuticals aims to provide innovative therapeutic options for patients suffering from various conditions. The company emphasizes research and development of new drug formulations and treatment approaches to meet the needs of patients and the medical community. Avadel Pharmaceuticals plc (AVDL) shares could be suitable for investors looking for investments in the pharmaceutical industry with a focus on innovative therapies and drug development for neurological and cardiovascular diseases.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Gregory J. Divis Jr.

Employees

188

Headquarters

Dublin

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.